Healthy volunteers 20 years of age or older at the time of obtaining consent Patients with mild cognitive impairment (MCI) 20 years of age or older at the time of obtaining consent Patients with Alzheimer'
Conditions
Sponsors
National Institute of Radiological Sciences
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: healthy volunteer 1. 20 years of age or older at the time of obtaining consent. For the judgment of whether or not subject cognitive function can be deemed normal. 2. In order to reduce gender bias, subjects will be selected to match the male-to-female ratios of the patient groups to the maximum extent possible. 3. Healthy subjects who have the ability to consent to participate in this study, to read and understand the informed consent form. Patients with MCI, AD, CBD, PSP, FTD and PARK8 1. Patients 20 years of age or older at the time of obtaining consent. 2. Patients with MCI and patients with AD: Patients meeting the inclusion criteria in the J-ADNI core study except for age. However, the range of CDR (Clinical dementia rating) in patients with AD will be 0.5-2, and the range of MMSE (Mini Mental State Examination) will be 26 points or less, and the acceptable range of drugs that can be used will be partially changed. Patients with CBD: Patients meeting the diagnostic criteria of the Mayo Clinic (Boeve BF, 2003) and/or the modified version of the Cambridge diagnostic criteria (Mathew R, 2011). Patients with PSP: Patients meeting the NINDS-SPSP diagnostic criteria (Litvan I, 1996). Patients with FTD: Patients meeting the diagnostic criteria of Neary et al. (Neary D, 1998), and/or patients diagnosed with FTD and parkinsonism linked to chromosome 17; FTDP-17 (MAPT) based on genetic testing (including presymptomatic carriers). Patients with PARK8: Patients diagnosed as PARK8 based on genetic testing. 3. Patients who can be accompanied by a legal guardian on the day of study participation at the NIRS. 4. Patients who can understand the outline of this study at the time consent is obtained. Two or more doctors in the collaborating study institutions and the NIRS will judge whether or not the patient can understand the study outline.
Exclusion criteria
Exclusion criteria: healthy volunteer 1. Subjects with organic brain complications/disorders (including a history of symptomatic cerebral infarction, Parkinson's disease and similar conditions). 2. Patients with substance-related disorders (including drug abuse). For the acceptable range of allowable drugs. 3. Subjects with severe physical complications/disorders or a history of such conditions and who are considered to be inappropriate for participation by the aforementioned doctors with responsibilities in this study. 4. Subjects with a pacemaker or other metallic medical device in the body (brain clip, bolts, etc.). 5. Subjects with tattoos. Subjects with claustrophobia. 6. Pregnant, possibly pregnant or lactating women. 7. From the standpoint of radiation exposure from a nuclear medicine scan, subjects who have participated in other nuclear medicine scans as healthy volunteers in the 6 months prior to the start of this study. 8. Subjects who are considered to be inappropriate for participation by doctors with responsibilities in this study. Patients with MCI, AD, CBD, PSP, FTD and PARK8 1. Patients with other organic brain complications/disorders (including a history of symptomatic cerebral infarction, Parkinson's disease and similar conditions). 2. Patients with substance-related disorders (including drug abuse). For the acceptable range of allowable drugs. 3. Patients with severe physical complications/disorders or a history of such conditions and who are considered to be inappropriate for participation by doctors with responsibilities in this study. 4. Patients with claustrophobia. 5. Pregnant, possibly pregnant or lactating women. 6. Patients who are considered to be inappropriate for participation by doctors with responsibilities in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Distribution volume and binding potential measured by positron emission tomography with [11C]PBB3 - Comparison between patients and age- and gender-matched healthy controls | — |
Countries
Japan
Contacts
Public Contactkazuko Suzuki
National Institute of Radiological Sciences Molecular Imaging Center
Outcome results
None listed